The first‐line treatment for advanced non‐small cell lung cancer (NSCLC) has changed with the approval of immune checkpoint inhibitors (ICIs), such as anti‐programmed death 1 (PD‐1) antibody and anti‐programmed death ligand 1 (PD‐L1) antibody. The gene discussed is CD274; the disease is non-small cell lung carcinoma.